RT Journal Article
SR Electronic
T1 Surgical and Medical Treatment of Clear Cell Ovarian Cancer: Results From the Multicenter Italian Trials in Ovarian Cancer (MITO) 9 Retrospective Study
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1063
OP 1070
DO 10.1097/IGC.0b013e318218f270
VO 21
IS 6
A1 Francescapaola Magazzino
A1 Dionyssios Katsaros
A1 Alessandro Ottaiano
A1 Angiolo Gadducci
A1 Carmela Pisano
A1 Roberto Sorio
A1 Emanuela Rabaiotti
A1 Giovanni Scambia
A1 Gennaro Cormio
A1 Luca Scarampi
A1 Stefano Greggi
A1 Antonella Savarese
A1 Marco Marinaccio
A1 Paolo Scollo
A1 Sandro Pignata
YR 2011
UL http://ijgc.bmj.com/content/21/6/1063.abstract
AB Objective: Clear cell ovarian carcinoma has a poorer prognosis compared with other histological subtypes.Materials and Methods: The Multicenter Italian Trials in Ovarian Cancer (MITO) 9 study retrospectively assessed an Italian cohort of patients with clear cell ovarian cancer observed in the years 1991-2007 in 20 Italian centers.Results: A total of 240 patients with ovarian cancer were analyzed. Forty-five percent of the patients had stage I disease. In 62.9%, clear cell histology was pure, whereas in the other cases, a mixed population was evident. Most of the cases underwent standard surgery, whereas in 7.1% of the patients, a fertility-sparing surgery was given. Lymphadenectomy was performed in 47.9% (115/240) of the patients (54.3% in stages I and II; 39.2% in advanced stage). Most of the patients were treated with platinum-based chemotherapy including paclitaxel in 52.9%. Disease-free survival was longer in patients undergoing lymphadenectomy at surgery (P = 0.0001), both in early stages (P = 0.0258) and in stage III and IV diseases (P = 0.0037). The impact of lymphadenectomy was also evident on overall survival in patients with advanced-stage disease. At multivariate analysis, lymphadenectomy (done vs not done) and stage (I and II vs III and IV) were independently associated with longer disease-free and overall survival, whereas front-line chemotherapy (with vs without taxanes) was not significant.Conclusion: This analysis suggests that lymphadenectomy has a strong prognostic role for clear cell ovarian cancer influencing disease-free survival and overall survival. The addition of paclitaxel to platinum-based chemotherapy does not affect the outcome.